SAG
CAPR icon

SageView Advisory Group’s Capricor Therapeutics CAPR Stock Holding History

SageView Advisory Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$578 Buy
+20
New +$261 ﹤0.01% 2434

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SageView Advisory Group's CAPR Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Capricor Therapeutics (CAPR) in Q4 2025: 20 shares worth $578. The stake represents ﹤0.01% of the portfolio and ranks #2434 among its holdings.

132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • SageView Advisory Group held 20 shares of Capricor Therapeutics worth $578 as of Q4 2025.
  • Capricor Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Capricor Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2434 holding.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.